AMTI Key Statistics, Chart & Performance
The current stock price of AMTI is 0.263 USD. In the past month the price increased by 57.01%. In the past year, price decreased by -37.38%.
AMTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About AMTI
Company Profile
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-06-05. The firm is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company’s pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.
Company Info
APPLIED MOLECULAR TRANSPORT
C/O The Corporation Trust Company, Corporation Trust Center, 1209 Orange St
Wilmington DELAWARE 94080 US
CEO: Tahir Mahmood
Employees: 79
Phone: 16503920420
APPLIED MOLECULAR TRANSPORT / AMTI FAQ
Can you describe the business of APPLIED MOLECULAR TRANSPORT?
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-06-05. The firm is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company’s pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.
What is the current price of AMTI stock?
The current stock price of AMTI is 0.263 USD. The price decreased by -14.3% in the last trading session.
Does APPLIED MOLECULAR TRANSPORT pay dividends?
AMTI does not pay a dividend.
What is the ChartMill rating of APPLIED MOLECULAR TRANSPORT stock?
AMTI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is APPLIED MOLECULAR TRANSPORT (AMTI) stock traded?
AMTI stock is listed on the Nasdaq exchange.
What do analysts say about APPLIED MOLECULAR TRANSPORT (AMTI) stock?
6 analysts have analysed AMTI and the average price target is 1.02 USD. This implies a price increase of 287.83% is expected in the next year compared to the current price of 0.263.
AMTI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AMTI. When comparing the yearly performance of all stocks, AMTI is one of the better performing stocks in the market, outperforming 77.29% of all stocks.
AMTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AMTI. AMTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AMTI Financial Highlights
Over the last trailing twelve months AMTI reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 45.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -373.95% | ||
| ROE | -461.67% | ||
| Debt/Equity | 0 |
AMTI Forecast & Estimates
6 analysts have analysed AMTI and the average price target is 1.02 USD. This implies a price increase of 287.83% is expected in the next year compared to the current price of 0.263.